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EDITORIAL
Can we prevent breast cancer?*
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Although our understanding of breast cancer has improved
enormously over the last two decades and treatment has
become more rational progress is slow and improvement in
case survival modest. Permutations of local surgery with and
without radiotherapy have in themselves not improved the
chances of long term survival, but have at least allowed us to
adopt a more conservative approach for women with the
most favourable stages of the disease. Adjuvant systemic
therapy has not reproduced the anticipated advantages that
experimental models might have suggested. No doubt with
the current generation of adjuvant systemic trials additional
modest gains will be discovered, but until we experience the
next conceptual shift in the biological management of breast
cancer, which may be decades away we have to turn to
primary and secondary preventive measures in our attempts
to reduce the impact of this disease on our Society.
Breast screening is not strictly a preventative measure, but
a case finding exercise aimed at reducing mortality by detect-
ing disease at a stage before it has had a chance to
disseminate. Despite the evidence of reduced mortality from
breast cancer in screened populations, critics continue to
argue that current screening guidelines are insupportable on
the basis of socio-economic cost benefit and harm benefit
ratios. Accepting the best case scenario for the results of
mammographic screening we can anticipate a 20 to 30%
reduction in breast cancer related deaths for women over the
age of 50 within the next decade. In absolute terms this still
remains a very modest gain and the majority of women
developing the disease are still doomed to die, whether it is
screen detected or clinically detected. The ultimate limitation
of secondary prevention depends on the unfortunate
biological truth that breast cancer, by the time it has reached
either mammographic or clinically detectable proportions has
had sufficient time in its natural history to express its lethal
potential for early dissemination.
This therefore leads us to consider strategies for the
primary prevention of breast cancer. These might be by
dietary manipulation or chemoprevention using agents such
as retinoids, contraceptives or tamoxifen.
The epidemiological evidence of an association between
dietary fat and the development of breast cancer is strong
and is supported by numerous animal models (Pritchard et
al., 1989). Dietary intervention is therefore one candidate for
the primary prevention of breast cancer. Reduction of fat
intake from a current average level of about 40% of calories
to about 20% would demand radical changes in diet and yet
experience in rural Chinese populations (Chen et al., 1987)
and amongst Seventh Day Adventists (Mills et al., 1988) fails
to demonstrate the predicted fall in breast cancer incidence
with very low fat intake. The slow changes in breast cancer
rates when low risk populations (Japanese) migrate to the
high risk areas (US) led to the conclusion that fat restriction
is important at a very young age and long term trials would
be needed to judge the effect of fat on breast cancer rates
(Cuzick 1988; Boyd 1990). The major disadvantages of this
approach is that maintaining a high compliance over a 10-
year period in a diet restricted group would be extremely
difficult (Prentice et al., 1988), although Boyd et al. (1990)
have demonstrated its feasibility.
The advantages ofchemoprevention compared with dietary
restriction are self-evident. Compliance with pill taking is
certainly not as complex as that ofdietary intervention, but it
is by no means straightforward. However, the main limita-
tion of a chemical approach to the prevention of cancer
concerns the relative rarity of this disease in any 1 year in the
life of a woman who is at average risk. Thus if you expose
the cohort of 1,000 women to the long term administration
of the drug and say it reduces the incidence of breast cancer
by 50%, then after 2 years' exposure one woman may have
benefited from this activity whilst 999 will have been exposed
to the potential of rare side effects. Ideally therefore we need
to search for a group of women at exceptionally high risk,
but unfortunately the majority of breast cancers occur in
women with no particular risk factors (Cuzick et al., 1986).
In the long term it is likely that recent developments in
molecular genetics will allow us to identify the 'fingerprints'
of those women who will develop the disease (Coles et al.,
1990). In the meantime therefore we would suggest that the
search for the chemoprevention of breast cancer should be an
incidental activity alongside the search for an intervention
that will improve the health and well being of all women in
our community. Thus most pre-menopausal women will
require safe and effective contraception at some time in their
life. The contraceptive pill that might incidentally reduce the
incidence of breast cancer, is not an unrealistic goal. Alterna-
tively, post-menopausal women are exposed to the risk of
osteoporosis and ischaemic heart disease as they grow older.
An endocrine approach that reduces both of these hazards,
might incidentally reduce the risk of breast cancer. For these
reasons we wish to concentrate on the prospects of develop-
ing an oral contraceptive pill that might incidentally prevent
breast cancer and the use of tamoxifen that might inciden-
tally reduce the risk of ischaemic heart disease or
osteoporosis.
Many studies have failed to demonstrate an increase in the
incidence of breast cancer in users of oral contraceptives
(OC's) (Wile & Disaia, 1989). In others (UK National Case
Control Study Group, 1989) an increased risk of breast
cancer has been shown for a total duration of oral contracep-
tive use of 49 to 96 months and a greater risk for 97 or more
months use. The food and drug administration (FDA) on
reviewing these conflicting reports has concluded that the
increased risk of breast cancers in users of OC's is not
sufficient to outweigh their benefits as a reliable method of
birth control (FDA Drug Bulletin, 1984). Whilst using pro-
gesterone only pills, protective effect was found against
breast cancer (The Centres for Disease Control Cancer &
Steroid Hormone Study, 1983) and the reduction in benign
breast disease was correlated with the amount of
progesterone in the oral contraceptive formulation (Royal
College of General Practitioners, 1977). Gestodene (17 -
Alpha - Ethynil - 13 - Beta - Ethyl - 17 - Beta - Hydroxy-
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4, 15 - Gonadiene - 3 - One) a new synthetic progestergene
has been shown to displace oestradiol from the oestrogen
receptors in malignant but not normal breast tissue. When
part of an oral contraceptive preparation it may prevent
binding of oestradiol not only by competing for the receptor
but also by binding to a novel protein specific to breast
cancer cells (Colletta et al., 1989). T47D breast cancer cells
are capable of responding to gestodene by the secretion of
growth inhibitory concentrations of the negative growth
modulator TGF beta. Its functional significance is suggested
by the fact that gestodene is both growth inhibitory for
breast cancer cells and inhibits the incorporation of radio
labelled nuclear type pre-cursors into cellular DNA (Colletta
et al., 1990). If it is truly breast cancer specific then the point
which it becomes involved during the progression from a
normal to a malignant breast epithelial cell might be of
greater significance in an interventional approach to the
treatment and possibly the prevention of breast cancer via
oral contraceptive use. As long as the breast epithelial cells
are proliferating normally, then gestodene could act slowly as
a progestergen, but if a breast cell starts progressing towards
malignancy then gestodene could induce the secretion of
TGF beta and differentially slow or inhibit the growth of the
pre-malignant cells. It is therefore not unrealistic to develop
an OC that will provide safe and convenient family planning
for many pre-menopausal women whilst incidentally reducing
the incidence of breast cancer.
Amongst the potential chemopreventive agents, tamoxifen
certainly has an enormous amount of indirect epidemio-
logical mechanistic and animal data to support its use (Jor-
dan, 1988). Breast cancer cells treated with tamoxifen
accumulate in GO/GI stages of the cell cycle with the resulting
inhibition of growth. Thus the drug is cytostatic in its anti-
tumour action (Love, 1989). In animal experiments, tamoxi-
fen inhibits the initiation and promotion of induced
mammary tumours (Gottardes & Jordan, 1987). Human hor-
mone dependant breast cell lines can be grown as solid
tumours in athymic mice under the influence of oestrogen,
whilst tamoxifen will inhibit oestrogen stimulated growth.
Once tamoxifen is stopped, oestrogen can cause the regrowth
of the tumours (Love, 1989). Tamoxifen has now found its
clinical place in both the palliation and the adjuvant treat-
ment of carcinoma of the breast. Event free survival and
overall survival has been improved for node positive and
node negative cases amongst post-menopausal women. Its
role in the management of pre-menopausal and oestrogen
receptor negative cases is controversial and the best that can
be said is that there has been no group of women with early
breast cancer who have been shown as wholly unresponsive
to adjuvant tamoxifen (Nato, 1988, Scottish Cancer Trial
Office, 1987).
Considering its use as a chemopreventive agent raises the
question of tamoxifen's long term side effects. In the short
term, the drug is acceptable in over 95% of women treated.
In recent large trials, approximately 4% of the recipients
stopped the drug because of nausea, hot flushes, depression
and vaginitis (Nato, 1988, Scottish Cancer Trial Office, 1987).
It is even possible that some of these patients would have
experienced a similar 'toxicity' using a placebo. Longer term
biological effects that require serious investigation are carcio-
genicity, coagulation, lipid metabolism bone mineral density
and psycho-sexual problems (Powles et al., 1989).
There is little evidence to suggest that tamoxifen in
humans causes an excess of other cancers. Two recent reports
drew attention to an increased risk of endometrial cancer
which may have been related to the high doses of tamoxifen
used in the Swedish trials compared with the rest of the
world (Hardell, 1988; Fornander et al., 1989).
In the lipid research prevalence study, protection against
arthrosclerotic heart disease could be accounted for by in-
creased levels of high density lipo protein cholesterol. Such
an increase has been found in treatment with tamoxifen
(Rossner & Wallgrew, 1984; Bruning et al., 1988; Powles et
al., 1990). There is an increased incidence of venous and
arterial thrombosis when tamoxifen is combined with
chemotherapy. However, treatment with tamoxifen alone has
not been associated with an increase incidence of either
arterial or venous events when compared to observation or
placebo treated patients. (Tormey, 1988; Caleffi et al., 1988).
Recent evidence from bone cultures suggests the presence
of oestrogen receptors in normal human osteoblast like cells
(Erikson et al., 1988). For this reason, clinical data on
humans concerning the effect of tamoxifen on bone mineral
metabolism are being evaluated. No difference in bone den-
sity was found between tamoxifen and placebo treated pre-
menopausal women with early breast cancer (Gotfredsen et
al., 1984). Similarly, no differences were found in bone den-
sity of post menopausal women treated for at least 2 years
with adjuvant tamoxifen (Love et al., 1988).
In pre-menopausal women with benign breast disease, no
significant alteration in bone density was seen (Fentiman et
al., 1989). A non-significant mean gain in bone mineral den-
sity was demonstrated in a post-menopausal group of women
with breast cancer who were treated with tamoxifen for 1
year (Turken et al., 1989). We await with interest the soon to
be completed ICRF/CRC study of the long term toxicity of
200 women entered into trials of adjuvant tamoxifen 5 to10
years ago. These data should finally confirm or refute the
safety and additional benefits of tamoxifen for well women.
Before we can adopt any of the proposed strategies out-
lined above, clinical trials have to be performed because
epidemiological data can only identify possible associations,
but rarely defines aetiology. We can learn a great deal from
animal studies, but translating the information to humans is
very uncertain and risky business. Performing clinical trials
of the prevention of breast cancer raises awesome
methodological and ethical issues. Are we in fact ready to
embark upon such a programme? If the answer is positive
then who will be chosen for such a clinical trial. We know
that only 25% of patients with breast cancer have at least
one known high risk factor (Dupont & Page, 1985). Recruit-
ment of the whole female population is not practical, because
of ethical and financial problems. If there is a population
with a high enough risk, one is willing to accept some side
effects. However in dealing with a very low risk population
one is not willing to tolerate any side effects. The
identification of a high risk, group together with the com-
pliance problem are the greatest obstacles to progress at the
moment. However the very important feasibility trial con-
ducted by Dr Trevor Powles and his colleagues at the Royal
Marsden Hospital (1989, 1990) demonstrates that these
problems are not insurmountable. Perhaps the best way to
conduct such a clinical trial is by recruitment of a volunteer
group of women, either highly motivated cohort who are
familiar with the importance of the problem such as nurses,
or a group ofvolunteers who are at a self perceived increased
risk and are anxious to joint such a study. Other sources of
volunteers would be from the screening clinics and amongst
women with proven benign breast disease at specialist breast
clinics.
As far as pre-menopausal women are concerned, no
feasibility study would be necessary for a trial of two con-
traceptive agents one of which would contain gestodene, as
these agents are already in use worldwide. However, the
dosages used for contraception are perhaps much smaller
than those needed for chemoprevention. Therefore, much
more work is needed in this area before embarking on a very
expensive trial of this design.
In contrast, the ground has been very well prepared for the
launch of a trial for peri and post menopausal women with
20mg a day of tamoxifen. A parallel perhaps can be drawn
with the use of aspirin to prevent heart disease amongst
doctors in which the short term side effects appear to be
greater than those of tamoxifen (Anti-Platelet Trialists Col-
laboration, 1988). In addition, some important pilot studies
using the retinoid 4-HPR are being conducted in Italy (For-
malli et al., 1989). The safety data are encouraging and we
may soon learn whether this agent is capable of reducing the
incidence of second breast cancers in patients who have been
treated in the past for carcinoma of the breast. A combina-CAN WE PREVENT BREAST CANCER? 207
tion of tamoxifen and 4-HPR may be synergistic in the
chemoprevention of breast cancer in humans as had been
shown in Sprauge-Dawley rats (Ratko et al., 1989). A fac-
torial 2 x 2 trial of 4-HPR and tamoxifen might therefore be
a very elegant approach to addressing both questions. How-
ever, the planning of such studies should not inhibit the
immediate launching of trials of tamoxifen as a single agent
in peri and post menopausal women identified at double or
more the risk of developing breast cancer in the future. Such
an initiative has been endorsed by the breast cancer trials
co-ordinating committee of the UKCCCR and it is to be
hoped that the funding agencies will allow the extension of
the feasibility study currently being run at the Royal Mars-
den Hospital to additional specialist centres throughout the
United Kingdom.
References
ANTI-PLATELET TRIALISTS' COLLABORATION (1988). Secondary
prevention of vascular disease by prolonged antiplatelet treat-
ment. Br. Med. J., 296, 320.
BOYD, N.F., COUSINS, M., LOCKWOOD, G. & TRITCHLER, D. (1990).
The feasibility of testing experimentally the dietary fat - breast
cancer hypothesis. Br. J. Cancer, 62, 878.
BRUNING, P.F., BONFER, J.M.G., HART, A.A.M. & 4 others (1988).
Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J.
Cancer, 58, 497.
CALEFFI, M., FENTIMAN, I.S., CLARK, G.M. & 5 others (1988).
Effects of Tamoxifen on oestrogen binding, lipid and lipoprotein
concentrations and blood clotting parameters in premenopausal
women with breast pain. J. Endocrinol., 119, 335.
COLES, C., THOMPSON, A.M., ELDER, P.A. & 9 others (1990).
Evidence implicating at least two genes on chromosone 17p in
breast carcinogenics. Lancet, 336, 761.
THE CENTRES FOR DISEASE CONTROL CANCER AND STEROID
HORMONE STUDY (1983). Long term oral contraceptive use and
the risk of breast cancer. JAMA, 249, 1591.
CHEN, J., CAMPBELL, T.C., JUNYAO, L. & 5 others (1987). The
dieting, lifestyles and mortality charcteristics of 65 rural popula-
tions in the Peoples Republic of China. Dir. Nuritional Sciences;
Cornell University.
COLLETTA, A.A., HOWELL, F.V. & BAUM, M. (1989). A novel bind-
ing site for a synthetic progestagen in breast cancer cells. J.
Steroid Biochem., 33, 1055.
COLLETTA, A.A.,, WAKEFIELD, L.M., HOWELL, F.V., DANIELPOUR,
D., BAUM, M. & SPORN, M.B. (1990). The growth inhibition of
human breast cancer cells by a novel synthetic progestin is partly
mediated by the induction of transforming growth factor beta.
Exp. Cell Res. (in press).
CUZICK, J., WANG, D.Y. & BULBROOK, R.O. (1986). The preventive
of breast cancer. Lancet, i, 83.
DUPONT, W.D. & PAGE, D.L. (1985). Risk factors for breast cancer
in women with proliferative breast disease. NEJM, 312, 146.
ERIKSON, E.F., COLVARD, D.S., BERG, N.J. & 4 others (1988).
Evidence of oestrogen receptor in normal human osteoblast-like
cells. Science, 241, 84.
FDA DRUG BULLETIN (1984). Oral Contraceptives and Cancer. 14,
2.
FENTIMAN, I.S., CALEFFI, M., RODIN, B. & 2 others (1989). Bone
mineral content of women receiving tamoxifen for mastalgia. J.
Cancer, 60, 262.
FORMALLI, F., CARSANA, R., COSTA, A. & 5 others (1989). Plasma
retinol reduction by the synthetic retinoid fenretinide: a one year
follow-up study of breast cancer patients. Cancer Res., 49 (in
press).
FORNANDER, T., RUTQVIST, L.E., CEDERMARK, B. & 9 others
(1989). Adjuvant tamoxifen in early breast cancer: occurrence of
new primary cancers. Lancet, i, 117.
GOTFREDSEN, A., CHRISTIANSEN, C. & PALSHOF, T. (1984). The
effect of tamoxifen on bone mineral content in premenopausal
women with breast cancer. Cancer, 53, 853.
GOTTARDES, M.M. & JORDAN, V.C. (1987). Antitumour actions of
keoxifene and tamoxifen in the N-nitrosemethylurea-induced rat
mammary carcinoma model. Cancer Res., 47, 4020.
HARDELL, K. (1988). Tamoxifen as risk factor for carcinoma of
corpus uteri. Lancet, ii, 563.
JORDAN, V.C. (1988). Chemosuppression of breast cancer with
Tamoxifen - Laboratory evidence and future clinical investiga-
tion. Cancer Invest., 6, 589.
LOVE, R.R., MAZESS, R.B., TORMEY, D.C. & 3 others (1988). Bone
mineral density in women with breast cancer treated for at least
two years with tamoxifen. Breast Cancer Res. Treatment, 12, 297.
LOVE, R.R. (1989). Tamoxifen therapy in primary breast cancer.
Biology, efficacy and side effects. J. Clin. Oncol., 7, 803.
MILLS, P.K., ANNEGERS, J.F. & PHILLIPS, R.L. (1988). Animal pro-
duct consumption and subsequent fatal heart cancer risk among
Seventh Day Adventists. Am. J. Epidemiol., 127, 440.
NATO (1988). Controlled trial of tamoxifen as a single adjuvant
tamoxifen in the management of early breast cancer. Br. J.
Cancer, 57, 608.
POWLES, T.J., HARDY, S.E., ASHLEY, G.M. & 9 others (1989). A pilot
trial evaluate the acute toxicity and feasibility of tamoxifen for
prevention of breast cancer. Br. J. Cancer, 60, 126.
POWLES, T.J., TILLYER, C.R., JONES, A.L. & 4 others (1990). Preven-
tion of breast cancer with tamoxifen - an update of the Royal
Marsden Hospital pilot programme. Eur. J. Cancer, 26, 680.
PRENTICE, R.L., KAKAR, F., HURSTING, S. & 3 others (1988).
Aspects of the rationale for the Women's Health Trial. J. Natl
Cancer Inst., 80, 802.
RATKO, T.A., DETRISAC, C.J., DINGER, M.N. & 3 others (1989).
Chemopreventive efficacy of combined retinoid and tamoxifen
treatment following surgical excision of a primary mammary
cancer in female rats. Cancer Res., 49, 4472.
ROSSNER, S. & WALLGREN, A. (1984). Serum lipoproteins and pro-
teins after breast cancer surgery and effects of tamoxifen.
Atherosclerosis, 52, 339.
ROYAL COLLEGE OF GENERAL PRACTITIONERS (1977). Effects on
hypertension and benign breast disease of progestagen com-
ponent in combined oral contraceptive. Lancet, i, 624.
SCOTTISH CANCER TRIAL OFFICE (1987). Adjuvant tamoxifen in
the management of operable breast cancer: the Scottish trial.
Lancet, U, 171.
TORMEY, D.C. (1988). Tamoxifen: transition from the laboratory to
clinical preventive chemosuppression. Cancer Invest., 6, 597.
TURKEN, S., SIRIS, E., SELDIN, D. & 3 others (1989). Effects of
tamoxifen on spinal bone density in women with breast cancer. J.
Natl Cancer Inst., 81, 1086.
UK NATIONAL CASE-CONTROL STUDY GROUP (1989). Oral con-
traceptive use and breast cancer risk in young women. Lancet, i,
973.
WILE, G.A. & DISAIA, P.J. (1989). Hormones and breast cancer. Am.
J. Surg., 157, 438.